Gurnee, IL, United States of America

Sheri L Crampton

This inventor holds 1 USPTO granted patent, plus 3 CIPO patents. Top assignee: Abbott Laboratories Corporation. Active years: 2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sheri L Crampton. Retrieved from https://idiyas.com/inventor/sheri-l-crampton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 40(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sheri L Crampton: Innovator in Pharmaceutical Formulations

Introduction

Sheri L Crampton is a notable inventor in the field of pharmaceuticals, particularly known for her work on extended release formulations. She is based in the United States and has made significant contributions to the development of improved pharmaceutical compositions.

Latest Patents

Sheri L Crampton's latest patents focus on "Extended Release Formulations Of Erythromycin Derivatives." These patents describe an extended release pharmaceutical composition that comprises an erythromycin derivative and a pharmaceutically acceptable polymer. The composition is designed to have an improved taste profile compared to immediate release compositions of the erythromycin derivative.

Career Highlights

Crampton has been associated with Abbott Laboratories Corporation, where she has contributed her expertise in pharmaceutical formulations. Her work has been instrumental in advancing the field of drug delivery systems.

Collaborations

Some of her notable coworkers include Laman A Al-Razzak and Linda E Gustavson, who have collaborated with her on various projects within the pharmaceutical domain.

Conclusion

Sheri L Crampton's innovative work in extended release formulations highlights her commitment to improving pharmaceutical compositions. Her contributions continue to impact the field positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…